A Phase 2, multicenter, open label, two parts clinical study to evaluate the efficacy and safety of safusidenib erbumine in patients with isocitrate dehydrogenase 1 (IDH1) mutant glioma
Study of Safusidenib in Patients with Brain Glioma
Sponsor: AnHeart Therapeutics Inc.
Enrolling: Male and Female Patients
IRB Number: AAAU6265
U.S. Govt. ID: NCT05303519
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to see how safe and effective Safusidenib erbumine, the study drug, is in treating brain glioma and to find the recommended dose of the study drug for clinical studies. Safusidenib is not Food and Drug Administration (FDA) approved.
Fabio Iwamoto, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Do you have a life expectancy of more than 3 months? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator